title: Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses.
abstract: The high error rates of viral RNA-dependent RNA polymerases create heterogeneous viral populations whose disparate RNA genomes affect each other's survival. We systematically screened the poliovirus genome and identified four sets of dominant mutations. Mutated alleles in capsid- and polymerase-coding regions resulted in dominant negative phenotypes, probably due to the proteins' oligomeric properties. We also identified dominant mutations in an RNA element required for priming RNA synthesis (CRE) and in the protein primer (VPg), suggesting that nonproductive priming intermediates are inhibitory. Mutations that inhibit the activity of viral proteinase 2A were dominant, arguing that inhibition of its known intramolecular activity creates a toxic product. Viral products that, when defective, dominantly interfere with growth of nondefective viruses will probably be excellent drug targets because drug-sensitive viruses should be dominant over drug-resistant variants. Accordingly, a virus sensitive to anticapsid compound WIN51711 dominantly inhibited the intracellular growth of a drug-resistant virus. Therefore, dominant inhibitor screening should validate or predict targets for antiviral therapy with reduced risk for drug resistance.
authors.affiliation: Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305-5124, USA.
authors.forename: Scott
authors.initials: S
authors.lastname: Crowder
authors.forename: Karla
authors.initials: K
authors.lastname: Kirkegaard
mesh_terms: D000483:Alleles; D000998:Antiviral Agents / Q000494:pharmacology; D036022:Capsid Proteins / Q000235:genetics; D003546:Cysteine Endopeptidases / Q000235:genetics; D024882:Drug Resistance, Viral; D016679:Genome, Viral; D006367:HeLa Cells; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology; D008958:Models, Molecular; D009154:Mutation; D010641:Phenotype; D017955:Poliovirus / Q000235:genetics* / Q000502:physiology; D014176:Protein Biosynthesis; D014764:Viral Proteins / Q000235:genetics*; D014779:Virus Replication / Q000187:drug effects / Q000235:genetics*
chemical_list: D000998:Antiviral Agents; D036022:Capsid Proteins; D007555:Isoxazoles; D014764:Viral Proteins; D003546:Cysteine Endopeptidases; C057400:picornain 2A, Picornavirus; C045978:disoxaril